Bullish on the prospects of the drug development pipeline, Bank of America significantly raised Eli Lilly's target price.
```
Based on Eli Lilly's strong drug R&D pipeline outlook and its leading position in the market for weight loss and diabetes drugs, Bank of America has significantly raised its price target for Eli Lilly from $950 to $1,286, implying a 22% upside, and reiterated its Buy rating.
On December 2, Bank of America analyst Tim Anderson said in a research report that Eli Lilly, relying on its leading position with weight loss and diabetes drugs and faster-than-expected progress in new drug development, will continue to achieve extraordinary growth for years to come.
Bank of America’s core reason for optimism about Eli Lilly lies in its GLP-1 drugs Zepbound and Mounjaro, which maintain "number one" status in the large obesity and diabetes markets. Anderson stated that while the field is competitive and complex, Eli Lilly remains firmly in the lead.
The bank also noted that Eli Lilly's progress in new drug development is outpacing expectations. Analysts expect the oral drug orforglipron to launch in early 2026, rather than the previously anticipated late 2026, which has boosted the company's revenue and earnings forecasts for the coming year.
In addition, the overall surge in the valuation of the large-cap biopharmaceutical sector is also a positive factor. Anderson believes that as the Trump administration's healthcare policy priorities become clearer, the market is once again favoring the sector. Eli Lilly’s share price has climbed a cumulative 36% so far this year.
Faster-than-expected new drug progress
The key catalyst for Bank of America’s raised price target is the progress in Eli Lilly’s new drug development pipeline exceeding expectations.
Anderson expects the oral GLP-1 drug orforglipron to be launched in early 2026, ahead of previous market expectations of late 2026. This timeline adjustment has prompted analysts to raise their revenue and earnings forecasts for Eli Lilly for the coming year.
Anderson noted:
"The company is about to launch its much-anticipated new oral GLP-1 drug orforglipron at an accelerated pace, having received one of the FDA’s first national priority review vouchers. The company’s guidance targets a market launch in March 2026."
Meanwhile, Eli Lilly is advancing an extensive phase III development program for its high-performance product retatrutide (also known as “triple G”), with initial results possibly released by year’s end. The simultaneous progress in multiple pipelines has strengthened market confidence in Eli Lilly’s long-term growth prospects.
GLP-1 drugs solidify market leadership
Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro maintain a leading edge in the highly competitive GLP-1 drug market.
Anderson wrote in the research report:
"Although the obesity category is complicated and has many moving parts, we continue to believe Eli Lilly will maintain a solid leading position, which will drive extraordinary growth for years to come. Considering this background, its valuation is justified."
The GLP-1 drug market is vast and rapidly growing. With its two products, Eli Lilly has consolidated its competitive position in the pharmaceutical industry, which is a major reason for Bank of America’s continued bullish stance.
Industry valuation regains support
The overall valuation increase of the large-cap biopharmaceutical sector provides additional support for Eli Lilly’s share price.
Anderson stated that as the Trump administration’s healthcare policy priorities become clearer, the market is once again embracing the sector, which has helped drive a rebound in industry valuations.
The clarification of this policy environment has reduced investor concerns about regulatory uncertainty in the pharmaceutical industry and created more favorable valuation conditions for large biopharma companies including Eli Lilly. Eli Lilly’s share price has surged 37% this year, outperforming the broader market.
Risk Warning and DisclaimerThe market has risks, investment needs caution. This article does not constitute individual investment advice and has not considered the unique investment objectives, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular situations. Investments made accordingly are at one's own risk. ```